Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Dimension gets National Institutes of Health Panel’s approval for phase 1/2 study of DTX301 By PBR Staff Writer
Dimension Therapeutics has secured approval from the National Institutes of Health’s Recombinant DNA Advisory Committee (RAC) for a phase 1/2 study protocol for DTX301 to treat Ornithine Transcarbamylase (OTC) deficiency.
Contract Research & Services > Clinical Trials > News
Collegium unveils positive topline results for Hydrocodone DETERx clinical study Collegium Pharmaceutical has unveiled positive topline results from a clinical study evaluating Hydrocodone DETERx as a second product candidate using its proprietary DETERx drug delivery technology platform.
Contract Research & Services > Clinical Trials > News Cellectis treats first patient in phase 1 trial of UCART19 in Pediatric Acute B-ALL Cellectis announced that the first patient has been treated in the Phase I study of UCART19 in pediatric acute B lymphoblastic leukemia (B-ALL) at the University College of London (UCL).
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
GSK’s triple COPD combination therapy meets two co-primary endpoints in phase III study
GlaxoSmithKline's (GSK) investigational once-daily closed triple combination therapy was superior to AstraZeneca's twice-daily Symbicort Turbohaler (budesonide/formoterol 400/12 mcg) in a phase III study in patients with chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Takeda starts world's first norovirus vaccine field trial
By PBR Staff Writer
Japan-based Takeda Pharmaceutical Company has started what it claims to be the world's first norovirus vaccine field trial.
Contract Research & Services > Clinical Trials > News
Scancell suspends dosing with current clinical trial supplies of SCIB1
Scancell is suspending dosing with the current clinical trial supplies of SCIB1 with immediate effect.
Contract Research & Services > Clinical Trials > News
Corbus completes patient enrollment in phase 2 trial of Resunab to treat diffuse cutaneous systemic sclerosis
Corbus Pharmaceuticals has completed patient enrollment in its Phase 2 clinical trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis ("systemic sclerosis").
Contract Research & Services > Clinical Trials > News
Oncobiologics’ phase 3 clinical plan for Humira biosimilar receives first EU CTA approval
By PBR Staff Writer
Clinical-stage biopharmaceutical Oncobiologics has announced the first of its European Union (EU) clinical trial authorization (CTA) approvals for global phase 3 program for ONS-3010, biosimilar to Humira.
Contract Research & Services > Clinical Trials > News
Merck's Keytruda beats out chemotherapy in phase 3 lung cancer trial
By PBR Staff Writer
A phase 3 trial assessing the use of Merck’s Keytruda (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1, met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Clindox Launches ePRO Module as Part of CRFweb at ‘Outsourcing Clinical Trials UK 2016’
The latest release incorporates an electronic Patient Reported Outcome (ePRO) module, which allows subjects to fill in their own data online between visits.
Contract Research & Services > Clinical Trials > Press Releases
Flex Pharma starts phase 2 efficacy study in multiple sclerosis
Flex Pharma has initiated a Phase 2 efficacy study in multiple sclerosis (MS) patients in Australia.
Contract Research & Services > Clinical Trials > News
Senhwa Biosciences enrolls first patient in phase I/II CX-5461 trial in triple negative breast cancer
Senhwa Biosciences announced enrollment of the first patient in a multicenter Phase I/II clinical trial to evaluate Senhwa's investigational product CX-5461 in triple-negative breast cancer (TNBC) patients with known BRCA1/2 mutation or Homologous Recombination Defect (HRD).
Contract Research & Services > Clinical Trials > News
twoXAR completes initial studies of new rheumatoid arthritis drug candidates
twoXAR has completed initial preclinical studies investigating novel rheumatoid arthritis (RA) drug candidates.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests